Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113062 | 0.74 | TAAR1 (0.36) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL23701389 | 0.74 | ALDH1A1 (0.38) | ESR1ESR2NR1H2NR1H3ALDH1A1 | |
| SCHEMBL3526796 | 0.72 | ESR1 (0.37) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL3888384 | 0.72 | ESR1 (0.37) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL29749402 | 0.72 | ESR1 (0.37) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL20328588 | 0.72 | ESR1 (0.37) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL6013056 | 0.70 | ESR1 (0.41) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL988384 | 0.70 | NR1H2 (0.48) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL15889153 | 0.70 | ESR1 (0.41) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL8381381 | 0.70 | TAAR1 (0.37) | ESR1ESR2MAPK1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107629069-B | Preparation method of acetyl coenzyme A carboxylase inhibitor | 中国药科大学 | 2023-01-24 | — | — | CN | claimed |
| US-11713329-B2 | Intermediates useful in the preparation of halichondrin compounds and methods for preparing the same | BEIJING TIENYI LUFU PHARMATECH CO. LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
| CN-107629069-B | Preparation method of acetyl coenzyme A carboxylase inhibitor | 中国药科大学 | 2023-01-24 | — | — | CN | disclosed |
| EP-3156077-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2017-04-19 | — | — | EP | disclosed |
| EP-2231195-B1 | TARGETING LIPIDS | ARBUTUS BIOPHARMA CORP (CA) | 2017-03-29 | — | — | EP | disclosed |
| US-6414160-B1 | REACTING 5-ALKOXY-2(3H)OXAZOLONE COMPOUND WITH ALDEHYDE COMPOUND IN PRESENCE OF LEWIS ACID CATALYST | UBE INDUSTRIES, LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1000937-A1 | PROCESS FOR PRODUCING 4-ALKOXYCARBONYL-2-OXAZOLIDINONE COMPOUNDS | UBE INDUSTRIES LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-5663342-A | GLUCOSIDASE INHIBITORS, ANTIVIRAL, ANTI-HIV | G. D. SEARLE & CO. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5612480-A | GLUCOSIDASE INHIBITORS | G. D. SEARLE & CO. (US) | 1997-03-18 | — | — | US | disclosed |
| US-5595981-A | GLUCOSIDASE INHIBITOR, VIRICIDE, NOJIRIMYCIN DERIVATIVES | G.D. SEARLE & CO. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5451679-A | GLUCOSIDASE INHIBITORS, VIRICIDES | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| WO-1995024392-A1 | 2-CHLORO AND 2-BROMO DERIVATIVES OF 1,5-IMINOSUGARS | G. D. SEARLE & CO. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713329-B2 | Intermediates useful in the preparation of halichondrin compounds and methods for preparing the same | ERLIN1, ERLIN2, MAN1B1 | ESR1 1407/4885ESR2 1162/4885MAPK1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.